JP2012515786A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012515786A5 JP2012515786A5 JP2011548104A JP2011548104A JP2012515786A5 JP 2012515786 A5 JP2012515786 A5 JP 2012515786A5 JP 2011548104 A JP2011548104 A JP 2011548104A JP 2011548104 A JP2011548104 A JP 2011548104A JP 2012515786 A5 JP2012515786 A5 JP 2012515786A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- methyl
- piperazin
- hetero
- pyrazin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000005842 heteroatom Chemical group 0.000 claims 123
- 125000000217 alkyl group Chemical group 0.000 claims 72
- 125000003118 aryl group Chemical group 0.000 claims 49
- 125000000753 cycloalkyl group Chemical group 0.000 claims 49
- -1 cyano, thio, oxy, hydroxy, carbonyloxy Chemical group 0.000 claims 34
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 27
- 150000001602 bicycloalkyls Chemical group 0.000 claims 27
- 125000004104 aryloxy group Chemical group 0.000 claims 24
- 229910052739 hydrogen Inorganic materials 0.000 claims 22
- 239000001257 hydrogen Substances 0.000 claims 22
- 150000001875 compounds Chemical class 0.000 claims 21
- 150000002431 hydrogen Chemical class 0.000 claims 20
- 150000003839 salts Chemical class 0.000 claims 20
- 125000003282 alkyl amino group Chemical group 0.000 claims 15
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 claims 15
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 15
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims 15
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 14
- 125000005843 halogen group Chemical group 0.000 claims 14
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 claims 13
- LAQJGAKLLZAETL-UHFFFAOYSA-N 2h-pyrazin-3-one Chemical compound O=C1CN=CC=N1 LAQJGAKLLZAETL-UHFFFAOYSA-N 0.000 claims 11
- 229940124530 sulfonamide Drugs 0.000 claims 11
- 150000003456 sulfonamides Chemical class 0.000 claims 11
- 150000001408 amides Chemical class 0.000 claims 10
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 10
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 5
- 125000005188 oxoalkyl group Chemical group 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 125000001841 imino group Chemical group [H]N=* 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 3
- 125000004944 pyrazin-3-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 101710179684 Poly [ADP-ribose] polymerase Proteins 0.000 claims 2
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 claims 2
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- PPAJOMSDKOMGSS-LJQANCHMSA-N (6R)-11-[[4-(4-chlorophenyl)piperazin-1-yl]methyl]-2,8,13-triazatricyclo[7.4.0.02,6]trideca-1(9),10,12-trien-7-one Chemical compound C1=CC(Cl)=CC=C1N1CCN(CC=2C=C3NC(=O)[C@H]4CCCN4C3=NC=2)CC1 PPAJOMSDKOMGSS-LJQANCHMSA-N 0.000 claims 1
- KZYUYYPRNXXFLG-SFHVURJKSA-N (6S)-11-[[(4-methoxyphenyl)methyl-methylamino]methyl]-2,8,13-triazatricyclo[7.4.0.02,6]trideca-1(9),10,12-trien-7-one Chemical compound C1=CC(OC)=CC=C1CN(C)CC1=CN=C(N2[C@@H](CCC2)C(=O)N2)C2=C1 KZYUYYPRNXXFLG-SFHVURJKSA-N 0.000 claims 1
- ADUITFBJMQEAIZ-IBGZPJMESA-N (6S)-11-[[4-(3,5-difluorophenyl)piperazin-1-yl]methyl]-2,8,13-triazatricyclo[7.4.0.02,6]trideca-1(9),10,12-trien-7-one Chemical compound FC1=CC(F)=CC(N2CCN(CC=3C=C4NC(=O)[C@@H]5CCCN5C4=NC=3)CC2)=C1 ADUITFBJMQEAIZ-IBGZPJMESA-N 0.000 claims 1
- DDLJIHMEYVIBFH-FQEVSTJZSA-N (6S)-11-[[4-(4-methylphenyl)piperazin-1-yl]methyl]-2,8,13-triazatricyclo[7.4.0.02,6]trideca-1(9),10,12-trien-7-one Chemical compound C1=CC(C)=CC=C1N1CCN(CC=2C=C3NC(=O)[C@@H]4CCCN4C3=NC=2)CC1 DDLJIHMEYVIBFH-FQEVSTJZSA-N 0.000 claims 1
- MSBZQSMESRJKGX-KRWDZBQOSA-N (6S)-11-[[4-(5-chloropyridin-2-yl)piperazin-1-yl]methyl]-2,8,13-triazatricyclo[7.4.0.02,6]trideca-1(9),10,12-trien-7-one Chemical compound N1=CC(Cl)=CC=C1N1CCN(CC=2C=C3NC(=O)[C@@H]4CCCN4C3=NC=2)CC1 MSBZQSMESRJKGX-KRWDZBQOSA-N 0.000 claims 1
- BNSGRNILDNFORU-IBGZPJMESA-N (6S)-11-[[4-[4-(trifluoromethyl)phenyl]piperazin-1-yl]methyl]-2,8,13-triazatricyclo[7.4.0.02,6]trideca-1(9),10,12-trien-7-one Chemical compound C1=CC(C(F)(F)F)=CC=C1N1CCN(CC=2C=C3NC(=O)[C@@H]4CCCN4C3=NC=2)CC1 BNSGRNILDNFORU-IBGZPJMESA-N 0.000 claims 1
- IQYXVRUKMCDRJI-KRWDZBQOSA-N (6S)-11-[[benzyl(methyl)amino]methyl]-2,8,13-triazatricyclo[7.4.0.02,6]trideca-1(9),10,12-trien-7-one Chemical compound O=C([C@@H]1CCCN1C1=NC=2)NC1=CC=2CN(C)CC1=CC=CC=C1 IQYXVRUKMCDRJI-KRWDZBQOSA-N 0.000 claims 1
- OGOPSDDRTUDWAI-FQEVSTJZSA-N (6ar)-3-[[4-(4-chlorophenyl)-3,6-dihydro-2h-pyridin-1-yl]methyl]-6a,7,9,10-tetrahydro-5h-pyrido[1,2]pyrazino[4,6-a][1,4]thiazin-6-one Chemical compound C1=CC(Cl)=CC=C1C(CC1)=CCN1CC1=CN=C(N2[C@@H](CSCC2)C(=O)N2)C2=C1 OGOPSDDRTUDWAI-FQEVSTJZSA-N 0.000 claims 1
- AADZTGMNVAPJIK-FQEVSTJZSA-N (6as)-3-[[4-(4-bromophenyl)piperazin-1-yl]methyl]-5,6a,7,8,9,10-hexahydrodipyrido[1,2-c:2',3'-f]pyrazin-6-one Chemical compound C1=CC(Br)=CC=C1N1CCN(CC=2C=C3NC(=O)[C@@H]4CCCCN4C3=NC=2)CC1 AADZTGMNVAPJIK-FQEVSTJZSA-N 0.000 claims 1
- UHGFSXBAGNWYEP-NRFANRHFSA-N (6as)-3-[[4-(4-chlorophenyl)-3,6-dihydro-2h-pyridin-1-yl]methyl]-5,6a,7,8,9,10-hexahydrodipyrido[1,2-c:2',3'-f]pyrazin-6-one Chemical compound C1=CC(Cl)=CC=C1C(CC1)=CCN1CC1=CN=C(N2[C@@H](CCCC2)C(=O)N2)C2=C1 UHGFSXBAGNWYEP-NRFANRHFSA-N 0.000 claims 1
- SELQHPXHMAWJJK-FQEVSTJZSA-N (6as)-3-[[4-(4-chlorophenyl)piperazin-1-yl]methyl]-5,6a,7,8,9,10-hexahydrodipyrido[1,2-c:2',3'-f]pyrazin-6-one Chemical compound C1=CC(Cl)=CC=C1N1CCN(CC=2C=C3NC(=O)[C@@H]4CCCCN4C3=NC=2)CC1 SELQHPXHMAWJJK-FQEVSTJZSA-N 0.000 claims 1
- RQZUMTAXPGLPTA-NRFANRHFSA-N (6as)-3-[[4-(4-chlorophenyl)piperidin-1-yl]methyl]-5,6a,7,8,9,10-hexahydrodipyrido[1,2-c:2',3'-f]pyrazin-6-one Chemical compound C1=CC(Cl)=CC=C1C1CCN(CC=2C=C3NC(=O)[C@@H]4CCCCN4C3=NC=2)CC1 RQZUMTAXPGLPTA-NRFANRHFSA-N 0.000 claims 1
- CMTDKKJGEUVCFN-SANMLTNESA-N (6as)-3-[[4-(4-phenylphenyl)piperazin-1-yl]methyl]-5,6a,7,8,9,10-hexahydrodipyrido[1,2-c:2',3'-f]pyrazin-6-one Chemical compound O=C([C@@H]1CCCCN1C1=NC=2)NC1=CC=2CN(CC1)CCN1C(C=C1)=CC=C1C1=CC=CC=C1 CMTDKKJGEUVCFN-SANMLTNESA-N 0.000 claims 1
- PEKGQBRIPBJYKL-DEOSSOPVSA-N (6as)-3-[[4-(4-pyrazin-2-ylphenyl)piperazin-1-yl]methyl]-5,6a,7,8,9,10-hexahydrodipyrido[1,2-c:2',3'-f]pyrazin-6-one Chemical compound O=C([C@@H]1CCCCN1C1=NC=2)NC1=CC=2CN(CC1)CCN1C(C=C1)=CC=C1C1=CN=CC=N1 PEKGQBRIPBJYKL-DEOSSOPVSA-N 0.000 claims 1
- AWIPFGOVKZAYBK-VWLOTQADSA-N (6as)-3-[[4-(4-pyridin-2-ylphenyl)piperazin-1-yl]methyl]-5,6a,7,8,9,10-hexahydrodipyrido[1,2-c:2',3'-f]pyrazin-6-one Chemical compound O=C([C@@H]1CCCCN1C1=NC=2)NC1=CC=2CN(CC1)CCN1C(C=C1)=CC=C1C1=CC=CC=N1 AWIPFGOVKZAYBK-VWLOTQADSA-N 0.000 claims 1
- NKKGGAZFAYKORV-VWLOTQADSA-N (6as)-3-[[4-(4-pyridin-3-ylphenyl)piperazin-1-yl]methyl]-5,6a,7,8,9,10-hexahydrodipyrido[1,2-c:2',3'-f]pyrazin-6-one Chemical compound O=C([C@@H]1CCCCN1C1=NC=2)NC1=CC=2CN(CC1)CCN1C(C=C1)=CC=C1C1=CC=CN=C1 NKKGGAZFAYKORV-VWLOTQADSA-N 0.000 claims 1
- HLRXLGWCCYHBOU-VWLOTQADSA-N (6as)-3-[[4-(4-pyridin-4-ylphenyl)piperazin-1-yl]methyl]-5,6a,7,8,9,10-hexahydrodipyrido[1,2-c:2',3'-f]pyrazin-6-one Chemical compound O=C([C@@H]1CCCCN1C1=NC=2)NC1=CC=2CN(CC1)CCN1C(C=C1)=CC=C1C1=CC=NC=C1 HLRXLGWCCYHBOU-VWLOTQADSA-N 0.000 claims 1
- YMEXLMCPEWLIMU-DEOSSOPVSA-N (6as)-3-[[4-(4-pyrimidin-5-ylphenyl)piperazin-1-yl]methyl]-5,6a,7,8,9,10-hexahydrodipyrido[1,2-c:2',3'-f]pyrazin-6-one Chemical compound O=C([C@@H]1CCCCN1C1=NC=2)NC1=CC=2CN(CC1)CCN1C(C=C1)=CC=C1C1=CN=CN=C1 YMEXLMCPEWLIMU-DEOSSOPVSA-N 0.000 claims 1
- DZVSBPFGVAVASI-QHCPKHFHSA-N (6as)-3-[[4-(4-thiophen-2-ylphenyl)piperazin-1-yl]methyl]-5,6a,7,8,9,10-hexahydrodipyrido[1,2-c:2',3'-f]pyrazin-6-one Chemical compound O=C([C@@H]1CCCCN1C1=NC=2)NC1=CC=2CN(CC1)CCN1C(C=C1)=CC=C1C1=CC=CS1 DZVSBPFGVAVASI-QHCPKHFHSA-N 0.000 claims 1
- PWQSVGZXVDVVLV-DEOSSOPVSA-N (6as)-3-[[4-(4-thiophen-3-ylphenyl)piperazin-1-yl]methyl]-5,6a,7,8,9,10-hexahydrodipyrido[1,2-c:2',3'-f]pyrazin-6-one Chemical compound O=C([C@@H]1CCCCN1C1=NC=2)NC1=CC=2CN(CC1)CCN1C(C=C1)=CC=C1C=1C=CSC=1 PWQSVGZXVDVVLV-DEOSSOPVSA-N 0.000 claims 1
- NVNLVHOZQOKXAM-DEOSSOPVSA-N (6as)-3-[[4-[4-(1-methylpyrazol-4-yl)phenyl]piperazin-1-yl]methyl]-5,6a,7,8,9,10-hexahydrodipyrido[1,2-c:2',3'-f]pyrazin-6-one Chemical compound C1=NN(C)C=C1C1=CC=C(N2CCN(CC=3C=C4NC(=O)[C@@H]5CCCCN5C4=NC=3)CC2)C=C1 NVNLVHOZQOKXAM-DEOSSOPVSA-N 0.000 claims 1
- YRDUYSLMGYOWPO-VWLOTQADSA-N (6as)-3-[[4-[4-(2-methoxypyridin-3-yl)phenyl]piperazin-1-yl]methyl]-5,6a,7,8,9,10-hexahydrodipyrido[1,2-c:2',3'-f]pyrazin-6-one Chemical compound COC1=NC=CC=C1C1=CC=C(N2CCN(CC=3C=C4NC(=O)[C@@H]5CCCCN5C4=NC=3)CC2)C=C1 YRDUYSLMGYOWPO-VWLOTQADSA-N 0.000 claims 1
- YRHBKZXXVMOEDZ-VWLOTQADSA-N (6as)-3-[[4-[4-(2-methoxypyridin-4-yl)phenyl]piperazin-1-yl]methyl]-5,6a,7,8,9,10-hexahydrodipyrido[1,2-c:2',3'-f]pyrazin-6-one Chemical compound C1=NC(OC)=CC(C=2C=CC(=CC=2)N2CCN(CC=3C=C4NC(=O)[C@@H]5CCCCN5C4=NC=3)CC2)=C1 YRHBKZXXVMOEDZ-VWLOTQADSA-N 0.000 claims 1
- MLUZYGPMYROSSB-DEOSSOPVSA-N (6as)-3-[[4-[4-(2-methoxypyrimidin-5-yl)phenyl]piperazin-1-yl]methyl]-5,6a,7,8,9,10-hexahydrodipyrido[1,2-c:2',3'-f]pyrazin-6-one Chemical compound C1=NC(OC)=NC=C1C1=CC=C(N2CCN(CC=3C=C4NC(=O)[C@@H]5CCCCN5C4=NC=3)CC2)C=C1 MLUZYGPMYROSSB-DEOSSOPVSA-N 0.000 claims 1
- KHIKTQUSCVHPBH-MHZLTWQESA-N (6as)-3-[[4-[4-(2-methylphenyl)phenyl]piperazin-1-yl]methyl]-5,6a,7,8,9,10-hexahydrodipyrido[1,2-c:2',3'-f]pyrazin-6-one Chemical compound CC1=CC=CC=C1C1=CC=C(N2CCN(CC=3C=C4NC(=O)[C@@H]5CCCCN5C4=NC=3)CC2)C=C1 KHIKTQUSCVHPBH-MHZLTWQESA-N 0.000 claims 1
- AYHGSEVPRQAODK-SANMLTNESA-N (6as)-3-[[4-[4-(2-methylpyridin-4-yl)phenyl]piperazin-1-yl]methyl]-5,6a,7,8,9,10-hexahydrodipyrido[1,2-c:2',3'-f]pyrazin-6-one Chemical compound C1=NC(C)=CC(C=2C=CC(=CC=2)N2CCN(CC=3C=C4NC(=O)[C@@H]5CCCCN5C4=NC=3)CC2)=C1 AYHGSEVPRQAODK-SANMLTNESA-N 0.000 claims 1
- HRFDVWYZZDDOFB-VWLOTQADSA-N (6as)-3-[[4-[4-(3-methoxypyridin-4-yl)phenyl]piperazin-1-yl]methyl]-5,6a,7,8,9,10-hexahydrodipyrido[1,2-c:2',3'-f]pyrazin-6-one Chemical compound COC1=CN=CC=C1C1=CC=C(N2CCN(CC=3C=C4NC(=O)[C@@H]5CCCCN5C4=NC=3)CC2)C=C1 HRFDVWYZZDDOFB-VWLOTQADSA-N 0.000 claims 1
- IKOAINFXYHFHOM-SANMLTNESA-N (6as)-3-[[4-[4-(3-methylpyridin-4-yl)phenyl]piperazin-1-yl]methyl]-5,6a,7,8,9,10-hexahydrodipyrido[1,2-c:2',3'-f]pyrazin-6-one Chemical compound CC1=CN=CC=C1C1=CC=C(N2CCN(CC=3C=C4NC(=O)[C@@H]5CCCCN5C4=NC=3)CC2)C=C1 IKOAINFXYHFHOM-SANMLTNESA-N 0.000 claims 1
- JKRXKFBHDKBQCR-DEOSSOPVSA-N (6as)-3-[[4-[4-(3-methylthiophen-2-yl)phenyl]piperazin-1-yl]methyl]-5,6a,7,8,9,10-hexahydrodipyrido[1,2-c:2',3'-f]pyrazin-6-one Chemical compound C1=CSC(C=2C=CC(=CC=2)N2CCN(CC=3C=C4NC(=O)[C@@H]5CCCCN5C4=NC=3)CC2)=C1C JKRXKFBHDKBQCR-DEOSSOPVSA-N 0.000 claims 1
- AWKIAHXVBHQHPS-SANMLTNESA-N (6as)-3-[[4-[4-(4-methylpyridin-2-yl)phenyl]piperazin-1-yl]methyl]-5,6a,7,8,9,10-hexahydrodipyrido[1,2-c:2',3'-f]pyrazin-6-one Chemical compound CC1=CC=NC(C=2C=CC(=CC=2)N2CCN(CC=3C=C4NC(=O)[C@@H]5CCCCN5C4=NC=3)CC2)=C1 AWKIAHXVBHQHPS-SANMLTNESA-N 0.000 claims 1
- ZPTQUNQCVZLEHK-VWLOTQADSA-N (6as)-3-[[4-[4-(4-methylthiophen-3-yl)phenyl]piperazin-1-yl]methyl]-5,6a,7,8,9,10-hexahydrodipyrido[1,2-c:2',3'-f]pyrazin-6-one Chemical compound CC1=CSC=C1C1=CC=C(N2CCN(CC=3C=C4NC(=O)[C@@H]5CCCCN5C4=NC=3)CC2)C=C1 ZPTQUNQCVZLEHK-VWLOTQADSA-N 0.000 claims 1
- WVFICLXFZQNNFP-DEOSSOPVSA-N (6as)-3-[[4-[4-(5-methylthiophen-2-yl)phenyl]piperazin-1-yl]methyl]-5,6a,7,8,9,10-hexahydrodipyrido[1,2-c:2',3'-f]pyrazin-6-one Chemical compound S1C(C)=CC=C1C1=CC=C(N2CCN(CC=3C=C4NC(=O)[C@@H]5CCCCN5C4=NC=3)CC2)C=C1 WVFICLXFZQNNFP-DEOSSOPVSA-N 0.000 claims 1
- PIMNAEQRVXQMJG-DEOSSOPVSA-N (6as)-3-[[4-[4-(6-aminopyridin-2-yl)phenyl]piperazin-1-yl]methyl]-5,6a,7,8,9,10-hexahydrodipyrido[1,2-c:2',3'-f]pyrazin-6-one Chemical compound NC1=CC=CC(C=2C=CC(=CC=2)N2CCN(CC=3C=C4NC(=O)[C@@H]5CCCCN5C4=NC=3)CC2)=N1 PIMNAEQRVXQMJG-DEOSSOPVSA-N 0.000 claims 1
- BDECMCAGCFNLOK-VWLOTQADSA-N (6as)-3-[[4-[4-(6-methoxypyridin-2-yl)phenyl]piperazin-1-yl]methyl]-5,6a,7,8,9,10-hexahydrodipyrido[1,2-c:2',3'-f]pyrazin-6-one Chemical compound COC1=CC=CC(C=2C=CC(=CC=2)N2CCN(CC=3C=C4NC(=O)[C@@H]5CCCCN5C4=NC=3)CC2)=N1 BDECMCAGCFNLOK-VWLOTQADSA-N 0.000 claims 1
- PVMFFIHFSCUCRG-VWLOTQADSA-N (6as)-3-[[4-[4-(6-methoxypyridin-3-yl)phenyl]piperazin-1-yl]methyl]-5,6a,7,8,9,10-hexahydrodipyrido[1,2-c:2',3'-f]pyrazin-6-one Chemical compound C1=NC(OC)=CC=C1C1=CC=C(N2CCN(CC=3C=C4NC(=O)[C@@H]5CCCCN5C4=NC=3)CC2)C=C1 PVMFFIHFSCUCRG-VWLOTQADSA-N 0.000 claims 1
- PGVYCKGGYHRELG-SANMLTNESA-N (6as)-3-[[4-[4-(6-methylpyridin-3-yl)phenyl]piperazin-1-yl]methyl]-5,6a,7,8,9,10-hexahydrodipyrido[1,2-c:2',3'-f]pyrazin-6-one Chemical compound C1=NC(C)=CC=C1C1=CC=C(N2CCN(CC=3C=C4NC(=O)[C@@H]5CCCCN5C4=NC=3)CC2)C=C1 PGVYCKGGYHRELG-SANMLTNESA-N 0.000 claims 1
- VVNJNQRCXJMDLR-MHZLTWQESA-N (6as)-3-[[4-[4-[2-(hydroxymethyl)phenyl]phenyl]piperazin-1-yl]methyl]-5,6a,7,8,9,10-hexahydrodipyrido[1,2-c:2',3'-f]pyrazin-6-one Chemical compound OCC1=CC=CC=C1C1=CC=C(N2CCN(CC=3C=C4NC(=O)[C@@H]5CCCCN5C4=NC=3)CC2)C=C1 VVNJNQRCXJMDLR-MHZLTWQESA-N 0.000 claims 1
- IJUYDXJYENPXCJ-IBGZPJMESA-N (s)-3-((4-(2,4-difluorophenyl)piperazin-1-yl)methyl)-6a,7,8,9-tetrahydropyrido[3,2-e]pyrrolo[1,2-a]pyrazin-6(5h)-one Chemical compound FC1=CC(F)=CC=C1N1CCN(CC=2C=C3NC(=O)[C@@H]4CCCN4C3=NC=2)CC1 IJUYDXJYENPXCJ-IBGZPJMESA-N 0.000 claims 1
- WXCXFGAVUXTISL-QHCPKHFHSA-N (s)-3-((4-(4-(pyrrolidine-1-carbonyl)phenyl)piperazin-1-yl)methyl)-6a,7,8,9-tetrahydropyrido[3,2-e]pyrrolo[1,2-a]pyrazin-6(5h)-one Chemical compound C=1C=C(N2CCN(CC=3C=C4NC(=O)[C@@H]5CCCN5C4=NC=3)CC2)C=CC=1C(=O)N1CCCC1 WXCXFGAVUXTISL-QHCPKHFHSA-N 0.000 claims 1
- PPAJOMSDKOMGSS-IBGZPJMESA-N (s)-3-((4-(4-chlorophenyl)piperazin-1-yl)methyl)-6a,7,8,9-tetrahydropyrido[3,2-e]pyrrolo[1,2-a]pyrazin-6(5h)-one Chemical compound C1=CC(Cl)=CC=C1N1CCN(CC=2C=C3NC(=O)[C@@H]4CCCN4C3=NC=2)CC1 PPAJOMSDKOMGSS-IBGZPJMESA-N 0.000 claims 1
- VAPIWZBXOBGUHC-FQEVSTJZSA-N (s)-3-((4-(4-fluoro-2-methylphenyl)piperazin-1-yl)methyl)-6a,7,8,9-tetrahydropyrido[3,2-e]pyrrolo[1,2-a]pyrazin-6(5h)-one Chemical compound CC1=CC(F)=CC=C1N1CCN(CC=2C=C3NC(=O)[C@@H]4CCCN4C3=NC=2)CC1 VAPIWZBXOBGUHC-FQEVSTJZSA-N 0.000 claims 1
- JXLUEBGLWGRHIZ-FQEVSTJZSA-N (s)-3-chloro-4-(4-((6-oxo-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2-a]pyrazin-3-yl)methyl)piperazin-1-yl)benzonitrile Chemical compound ClC1=CC(C#N)=CC=C1N1CCN(CC=2C=C3NC(=O)[C@@H]4CCCN4C3=NC=2)CC1 JXLUEBGLWGRHIZ-FQEVSTJZSA-N 0.000 claims 1
- FOQUHTKZQKLQFS-QFIPXVFZSA-N (s)-3-chloro-n-cyclopropyl-4-(4-((6-oxo-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2-a]pyrazin-3-yl)methyl)piperazin-1-yl)benzamide Chemical compound C=1C=C(N2CCN(CC=3C=C4NC(=O)[C@@H]5CCCN5C4=NC=3)CC2)C(Cl)=CC=1C(=O)NC1CC1 FOQUHTKZQKLQFS-QFIPXVFZSA-N 0.000 claims 1
- OZTSXFIBVZAPEL-NRFANRHFSA-N (s)-3-chloro-n-ethyl-4-(4-((6-oxo-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2-a]pyrazin-3-yl)methyl)piperazin-1-yl)benzamide Chemical compound ClC1=CC(C(=O)NCC)=CC=C1N1CCN(CC=2C=C3NC(=O)[C@@H]4CCCN4C3=NC=2)CC1 OZTSXFIBVZAPEL-NRFANRHFSA-N 0.000 claims 1
- FNVLKAYQAGIFKZ-QFIPXVFZSA-N (s)-3-chloro-n-isopropyl-4-(4-((6-oxo-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2-a]pyrazin-3-yl)methyl)piperazin-1-yl)benzamide Chemical compound ClC1=CC(C(=O)NC(C)C)=CC=C1N1CCN(CC=2C=C3NC(=O)[C@@H]4CCCN4C3=NC=2)CC1 FNVLKAYQAGIFKZ-QFIPXVFZSA-N 0.000 claims 1
- KHZVOGCESIZZDS-FQEVSTJZSA-N (s)-3-chloro-n-methyl-4-(4-((6-oxo-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2-a]pyrazin-3-yl)methyl)piperazin-1-yl)benzamide Chemical compound ClC1=CC(C(=O)NC)=CC=C1N1CCN(CC=2C=C3NC(=O)[C@@H]4CCCN4C3=NC=2)CC1 KHZVOGCESIZZDS-FQEVSTJZSA-N 0.000 claims 1
- NAIXRQYFGYHGBG-FQEVSTJZSA-N (s)-3-fluoro-4-(4-((6-oxo-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2-a]pyrazin-3-yl)methyl)piperazin-1-yl)benzonitrile Chemical compound FC1=CC(C#N)=CC=C1N1CCN(CC=2C=C3NC(=O)[C@@H]4CCCN4C3=NC=2)CC1 NAIXRQYFGYHGBG-FQEVSTJZSA-N 0.000 claims 1
- MQNHZGGPZLIVLI-QFIPXVFZSA-N (s)-3-fluoro-n-isopropyl-4-(4-((6-oxo-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2-a]pyrazin-3-yl)methyl)piperazin-1-yl)benzamide Chemical compound FC1=CC(C(=O)NC(C)C)=CC=C1N1CCN(CC=2C=C3NC(=O)[C@@H]4CCCN4C3=NC=2)CC1 MQNHZGGPZLIVLI-QFIPXVFZSA-N 0.000 claims 1
- QAMJZTLFBOPTNQ-FQEVSTJZSA-N (s)-3-fluoro-n-methyl-4-(4-((6-oxo-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2-a]pyrazin-3-yl)methyl)piperazin-1-yl)benzamide Chemical compound FC1=CC(C(=O)NC)=CC=C1N1CCN(CC=2C=C3NC(=O)[C@@H]4CCCN4C3=NC=2)CC1 QAMJZTLFBOPTNQ-FQEVSTJZSA-N 0.000 claims 1
- WQKKUQDJDLOLIP-NRFANRHFSA-N (s)-3-methyl-4-(4-((6-oxo-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2-a]pyrazin-3-yl)methyl)piperazin-1-yl)benzonitrile Chemical compound CC1=CC(C#N)=CC=C1N1CCN(CC=2C=C3NC(=O)[C@@H]4CCCN4C3=NC=2)CC1 WQKKUQDJDLOLIP-NRFANRHFSA-N 0.000 claims 1
- ZLGLBIIZJMUCHB-IBGZPJMESA-N (s)-4-(4-((6-oxo-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2-a]pyrazin-3-yl)methyl)piperazin-1-yl)benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1N1CCN(CC=2C=C3NC(=O)[C@@H]4CCCN4C3=NC=2)CC1 ZLGLBIIZJMUCHB-IBGZPJMESA-N 0.000 claims 1
- CKGPVOCSMDTBML-IBGZPJMESA-N (s)-4-(4-((6-oxo-6,6a,7,8-tetrahydro-5h-azeto[1,2-a]pyrido[3,2-e]pyrazin-3-yl)methyl)piperazin-1-yl)benzonitrile Chemical compound O=C([C@@H]1CCN1C1=NC=2)NC1=CC=2CN(CC1)CCN1C1=CC=C(C#N)C=C1 CKGPVOCSMDTBML-IBGZPJMESA-N 0.000 claims 1
- IXVHGZHCZQMZNK-KRWDZBQOSA-N (s)-6-(4((6-oxo-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2-a]pyrazin-3-yl)methyl)piperazin-1-yl)nicotinic acid Chemical compound N1=CC(C(=O)O)=CC=C1N1CCN(CC=2C=C3NC(=O)[C@@H]4CCCN4C3=NC=2)CC1 IXVHGZHCZQMZNK-KRWDZBQOSA-N 0.000 claims 1
- XIWPJLUXWWVNST-QFIPXVFZSA-N (s)-n-cyclopropyl-3-fluoro-4-(4-((6-oxo-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2-a]pyrazin-3-yl)methyl)piperazin-1-yl)benzamide Chemical compound C=1C=C(N2CCN(CC=3C=C4NC(=O)[C@@H]5CCCN5C4=NC=3)CC2)C(F)=CC=1C(=O)NC1CC1 XIWPJLUXWWVNST-QFIPXVFZSA-N 0.000 claims 1
- SVIWPAOOEMGLFF-QHCPKHFHSA-N (s)-n-cyclopropyl-3-methyl-4-(4-((6-oxo-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2-a]pyrazin-3-yl)methyl)piperazin-1-yl)b enzamide Chemical compound C=1C=C(N2CCN(CC=3C=C4NC(=O)[C@@H]5CCCN5C4=NC=3)CC2)C(C)=CC=1C(=O)NC1CC1 SVIWPAOOEMGLFF-QHCPKHFHSA-N 0.000 claims 1
- IAELLELRCVJROM-QFIPXVFZSA-N (s)-n-cyclopropyl-4-(4-((6-oxo-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2-a]pyrazin-3-yl)methyl)piperazin-1-yl)benzamide Chemical compound C=1C=C(N2CCN(CC=3C=C4NC(=O)[C@@H]5CCCN5C4=NC=3)CC2)C=CC=1C(=O)NC1CC1 IAELLELRCVJROM-QFIPXVFZSA-N 0.000 claims 1
- PLGCNXGZHVZFTB-FQEVSTJZSA-N (s)-n-cyclopropyl-6-(4-((6-oxo-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2-a]pyrazin-3-yl)methyl)piperazin-1-yl)nicotinamide Chemical compound C=1C=C(N2CCN(CC=3C=C4NC(=O)[C@@H]5CCCN5C4=NC=3)CC2)N=CC=1C(=O)NC1CC1 PLGCNXGZHVZFTB-FQEVSTJZSA-N 0.000 claims 1
- CUDNLGMXSRNASQ-FQEVSTJZSA-N (s)-n-ethyl-2,5-difluoro-4-(4-((6-oxo-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2-a]pyrazin-3-yl)methyl)piperazin-1-yl)benzamide Chemical compound C1=C(F)C(C(=O)NCC)=CC(F)=C1N1CCN(CC=2C=C3NC(=O)[C@@H]4CCCN4C3=NC=2)CC1 CUDNLGMXSRNASQ-FQEVSTJZSA-N 0.000 claims 1
- FDBOAPDDGJJAHV-NRFANRHFSA-N (s)-n-ethyl-2-fluoro-4-(4-((6-oxo-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2-a]pyrazin-3-yl)methyl)piperazin-1-yl)benzamide Chemical compound C1=C(F)C(C(=O)NCC)=CC=C1N1CCN(CC=2C=C3NC(=O)[C@@H]4CCCN4C3=NC=2)CC1 FDBOAPDDGJJAHV-NRFANRHFSA-N 0.000 claims 1
- IQMHHPRPWRFIAR-NRFANRHFSA-N (s)-n-ethyl-3-fluoro-4-(4-((6-oxo-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2-a]pyrazin-3-yl)methyl)piperazin-1-yl)benzamide Chemical compound FC1=CC(C(=O)NCC)=CC=C1N1CCN(CC=2C=C3NC(=O)[C@@H]4CCCN4C3=NC=2)CC1 IQMHHPRPWRFIAR-NRFANRHFSA-N 0.000 claims 1
- JDXBBXHDCDMRAI-QFIPXVFZSA-N (s)-n-ethyl-3-methyl-4-(4-((6-oxo-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2-a]pyrazin-3-yl)methyl)piperazin-1-yl)benzamide Chemical compound CC1=CC(C(=O)NCC)=CC=C1N1CCN(CC=2C=C3NC(=O)[C@@H]4CCCN4C3=NC=2)CC1 JDXBBXHDCDMRAI-QFIPXVFZSA-N 0.000 claims 1
- JCJXAMFPGJGHDE-NRFANRHFSA-N (s)-n-ethyl-4-(4-((6-oxo-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2-a]pyrazin-3-yl)methyl)piperazin-1-yl)benzamide Chemical compound C1=CC(C(=O)NCC)=CC=C1N1CCN(CC=2C=C3NC(=O)[C@@H]4CCCN4C3=NC=2)CC1 JCJXAMFPGJGHDE-NRFANRHFSA-N 0.000 claims 1
- QWHQAPPPWWIOIF-IBGZPJMESA-N (s)-n-ethyl-6-(4-((6-oxo-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2-a]pyrazin-3-yl)methyl)piperazin-1-yl)nicotinamide Chemical compound N1=CC(C(=O)NCC)=CC=C1N1CCN(CC=2C=C3NC(=O)[C@@H]4CCCN4C3=NC=2)CC1 QWHQAPPPWWIOIF-IBGZPJMESA-N 0.000 claims 1
- WUOPXLCELLIDBY-QFIPXVFZSA-N (s)-n-ethyl-n-methyl-4-(4-((6-oxo-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2-a]pyrazin-3-yl)methyl)piperazin-1-yl)benzamide Chemical compound C1=CC(C(=O)N(C)CC)=CC=C1N1CCN(CC=2C=C3NC(=O)[C@@H]4CCCN4C3=NC=2)CC1 WUOPXLCELLIDBY-QFIPXVFZSA-N 0.000 claims 1
- DUYXSWHPKVYAGO-QFIPXVFZSA-N (s)-n-isopropyl-4-(4-((6-oxo-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2-a]pyrazin-3-yl)methyl)piperazin-1-yl)benzamide Chemical compound C1=CC(C(=O)NC(C)C)=CC=C1N1CCN(CC=2C=C3NC(=O)[C@@H]4CCCN4C3=NC=2)CC1 DUYXSWHPKVYAGO-QFIPXVFZSA-N 0.000 claims 1
- DXFWZZTUEGKQMI-FQEVSTJZSA-N (s)-n-isopropyl-6-(4-((6-oxo-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2-a]pyrazin-3-yl)methyl)piperazin-1-yl)nicotinamide Chemical compound N1=CC(C(=O)NC(C)C)=CC=C1N1CCN(CC=2C=C3NC(=O)[C@@H]4CCCN4C3=NC=2)CC1 DXFWZZTUEGKQMI-FQEVSTJZSA-N 0.000 claims 1
- JGTZRVFJIMUKHO-FQEVSTJZSA-N (s)-n-methyl-4-(4-((6-oxo-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2-a]pyrazin-3-yl)methyl)piperazin-1-yl)benzamide Chemical compound C1=CC(C(=O)NC)=CC=C1N1CCN(CC=2C=C3NC(=O)[C@@H]4CCCN4C3=NC=2)CC1 JGTZRVFJIMUKHO-FQEVSTJZSA-N 0.000 claims 1
- WBQJYGLXKWXXQU-FQEVSTJZSA-N (s)-n-methyl-4-(4-((6-oxo-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2-a]pyrazin-3-yl)methyl)piperazin-1-yl)benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)NC)=CC=C1N1CCN(CC=2C=C3NC(=O)[C@@H]4CCCN4C3=NC=2)CC1 WBQJYGLXKWXXQU-FQEVSTJZSA-N 0.000 claims 1
- PVBIEGJRECSVFB-SFHVURJKSA-N (s)-n-methyl-6-(4-((6-oxo-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2-a]pyrazin-3-yl)methyl)piperazin-1-yl)nicotinamide Chemical compound N1=CC(C(=O)NC)=CC=C1N1CCN(CC=2C=C3NC(=O)[C@@H]4CCCN4C3=NC=2)CC1 PVBIEGJRECSVFB-SFHVURJKSA-N 0.000 claims 1
- LCKZFXFTIFZJAD-UHFFFAOYSA-N 11-[[4-(4-chlorophenyl)-3,6-dihydro-2H-pyridin-1-yl]methyl]-2,4,8,13-tetrazatricyclo[7.4.0.02,6]trideca-1(9),3,5,10,12-pentaen-7-one Chemical compound C1=CC(Cl)=CC=C1C(CC1)=CCN1CC1=CN=C2N3C=NC=C3C(=O)NC2=C1 LCKZFXFTIFZJAD-UHFFFAOYSA-N 0.000 claims 1
- YTRWGCUVTKXDTR-UHFFFAOYSA-N 11-[[4-(4-chlorophenyl)-3,6-dihydro-2H-pyridin-1-yl]methyl]-2,5,8,13-tetrazatricyclo[7.4.0.02,6]trideca-1(9),3,5,10,12-pentaen-7-one Chemical compound C1=CC(Cl)=CC=C1C(CC1)=CCN1CC1=CN=C2N3C=CN=C3C(=O)NC2=C1 YTRWGCUVTKXDTR-UHFFFAOYSA-N 0.000 claims 1
- WYIZZTHRNWSIGO-IBGZPJMESA-N 2,5-difluoro-4-[4-[[(6S)-7-oxo-2,8,13-triazatricyclo[7.4.0.02,6]trideca-1(9),10,12-trien-11-yl]methyl]piperazin-1-yl]benzonitrile Chemical compound C1=C(C#N)C(F)=CC(N2CCN(CC=3C=C4NC(=O)[C@@H]5CCCN5C4=NC=3)CC2)=C1F WYIZZTHRNWSIGO-IBGZPJMESA-N 0.000 claims 1
- SJVFOPBDZKJRJN-FQEVSTJZSA-N 2,6-difluoro-4-[4-[[(6S)-7-oxo-2,8,13-triazatricyclo[7.4.0.02,6]trideca-1(9),10,12-trien-11-yl]methyl]piperazin-1-yl]benzonitrile Chemical compound FC1=C(C#N)C(F)=CC(N2CCN(CC=3C=C4NC(=O)[C@@H]5CCCN5C4=NC=3)CC2)=C1 SJVFOPBDZKJRJN-FQEVSTJZSA-N 0.000 claims 1
- BQLWSBVKPIIDPB-FQEVSTJZSA-N 2-fluoro-4-[4-[[(6S)-7-oxo-2,8,13-triazatricyclo[7.4.0.02,6]trideca-1(9),10,12-trien-11-yl]methyl]piperazin-1-yl]benzonitrile Chemical compound C1=C(C#N)C(F)=CC(N2CCN(CC=3C=C4NC(=O)[C@@H]5CCCN5C4=NC=3)CC2)=C1 BQLWSBVKPIIDPB-FQEVSTJZSA-N 0.000 claims 1
- UHGFSXBAGNWYEP-UHFFFAOYSA-N 3-[[4-(4-chlorophenyl)-3,6-dihydro-2h-pyridin-1-yl]methyl]-5,6a,7,8,9,10-hexahydrodipyrido[1,2-c:2',3'-f]pyrazin-6-one Chemical compound C1=CC(Cl)=CC=C1C(CC1)=CCN1CC1=CN=C(N2C(CCCC2)C(=O)N2)C2=C1 UHGFSXBAGNWYEP-UHFFFAOYSA-N 0.000 claims 1
- OGOPSDDRTUDWAI-UHFFFAOYSA-N 3-[[4-(4-chlorophenyl)-3,6-dihydro-2h-pyridin-1-yl]methyl]-6a,7,9,10-tetrahydro-5h-pyrido[1,2]pyrazino[4,6-a][1,4]thiazin-6-one Chemical compound C1=CC(Cl)=CC=C1C(CC1)=CCN1CC1=CN=C(N2C(CSCC2)C(=O)N2)C2=C1 OGOPSDDRTUDWAI-UHFFFAOYSA-N 0.000 claims 1
- SELQHPXHMAWJJK-UHFFFAOYSA-N 3-[[4-(4-chlorophenyl)piperazin-1-yl]methyl]-5,6a,7,8,9,10-hexahydrodipyrido[1,2-c:2',3'-f]pyrazin-6-one Chemical compound C1=CC(Cl)=CC=C1N1CCN(CC=2C=C3NC(=O)C4CCCCN4C3=NC=2)CC1 SELQHPXHMAWJJK-UHFFFAOYSA-N 0.000 claims 1
- ZNCNVTDISAFGOE-UHFFFAOYSA-N 3-[[4-(4-chlorophenyl)piperazin-1-yl]methyl]-6a,7,9,10-tetrahydro-5h-pyrido[1,2]pyrazino[4,6-a][1,4]oxazin-6-one Chemical compound C1=CC(Cl)=CC=C1N1CCN(CC=2C=C3NC(=O)C4COCCN4C3=NC=2)CC1 ZNCNVTDISAFGOE-UHFFFAOYSA-N 0.000 claims 1
- OCCSDPKIBXLCRJ-UHFFFAOYSA-N 3-[[4-(4-chlorophenyl)piperazin-1-yl]methyl]-6a,7,9,10-tetrahydro-5h-pyrido[1,2]pyrazino[4,6-a][1,4]thiazin-6-one Chemical compound C1=CC(Cl)=CC=C1N1CCN(CC=2C=C3NC(=O)C4CSCCN4C3=NC=2)CC1 OCCSDPKIBXLCRJ-UHFFFAOYSA-N 0.000 claims 1
- RQZUMTAXPGLPTA-UHFFFAOYSA-N 3-[[4-(4-chlorophenyl)piperidin-1-yl]methyl]-5,6a,7,8,9,10-hexahydrodipyrido[1,2-c:2',3'-f]pyrazin-6-one Chemical compound C1=CC(Cl)=CC=C1C1CCN(CC=2C=C3NC(=O)C4CCCCN4C3=NC=2)CC1 RQZUMTAXPGLPTA-UHFFFAOYSA-N 0.000 claims 1
- YDFHXXPSBXGPSG-KKSFZXQISA-N 4-[(3s)-4-[[(6ar)-6-oxo-6a,7,9,10-tetrahydro-5h-pyrido[1,2]pyrazino[4,6-a][1,4]thiazin-3-yl]methyl]-3-methylpiperazin-1-yl]benzonitrile Chemical compound C([C@@H](N(CC1)CC=2C=C3NC(=O)[C@@H]4CSCCN4C3=NC=2)C)N1C1=CC=C(C#N)C=C1 YDFHXXPSBXGPSG-KKSFZXQISA-N 0.000 claims 1
- UHFLBVRQGQYQSY-QFIPXVFZSA-N 4-[4-[[(6ar)-6-oxo-6a,7,9,10-tetrahydro-5h-pyrido[1,2]pyrazino[4,6-a][1,4]thiazin-3-yl]methyl]piperazin-1-yl]-n-cyclopropylbenzamide Chemical compound C=1C=C(N2CCN(CC=3C=C4NC(=O)[C@@H]5CSCCN5C4=NC=3)CC2)C=CC=1C(=O)NC1CC1 UHFLBVRQGQYQSY-QFIPXVFZSA-N 0.000 claims 1
- COYPKBHELNSTBR-NRFANRHFSA-N 4-[4-[[(6ar)-6-oxo-6a,7,9,10-tetrahydro-5h-pyrido[1,2]pyrazino[4,6-a][1,4]thiazin-3-yl]methyl]piperazin-1-yl]-n-ethylbenzamide Chemical compound C1=CC(C(=O)NCC)=CC=C1N1CCN(CC=2C=C3NC(=O)[C@@H]4CSCCN4C3=NC=2)CC1 COYPKBHELNSTBR-NRFANRHFSA-N 0.000 claims 1
- CEQXKCUENVPGCC-FQEVSTJZSA-N 4-[4-[[(6ar)-6-oxo-6a,7,9,10-tetrahydro-5h-pyrido[1,2]pyrazino[4,6-a][1,4]thiazin-3-yl]methyl]piperazin-1-yl]-n-methylbenzamide Chemical compound C1=CC(C(=O)NC)=CC=C1N1CCN(CC=2C=C3NC(=O)[C@@H]4CSCCN4C3=NC=2)CC1 CEQXKCUENVPGCC-FQEVSTJZSA-N 0.000 claims 1
- QMLGFBXRJBLSKM-IBGZPJMESA-N 4-[4-[[(6ar)-6-oxo-6a,7,9,10-tetrahydro-5h-pyrido[1,2]pyrazino[4,6-a][1,4]thiazin-3-yl]methyl]piperazin-1-yl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1N1CCN(CC=2C=C3NC(=O)[C@@H]4CSCCN4C3=NC=2)CC1 QMLGFBXRJBLSKM-IBGZPJMESA-N 0.000 claims 1
- MOKDCYQYOGLLTO-FQEVSTJZSA-N 4-[4-[[(6ar)-6-oxo-6a,7,9,10-tetrahydro-5h-pyrido[1,2]pyrazino[4,6-a][1,4]thiazin-3-yl]methyl]piperazin-1-yl]benzonitrile Chemical compound O=C([C@@H]1CSCCN1C1=NC=2)NC1=CC=2CN(CC1)CCN1C1=CC=C(C#N)C=C1 MOKDCYQYOGLLTO-FQEVSTJZSA-N 0.000 claims 1
- ZBIXBAYEOLPYRG-QFIPXVFZSA-N 4-[4-[[(6as)-6-oxo-5,6a,7,8,9,10-hexahydrodipyrido[1,2-c:2',3'-f]pyrazin-3-yl]methyl]piperazin-1-yl]-3-chloro-n-ethylbenzamide Chemical compound ClC1=CC(C(=O)NCC)=CC=C1N1CCN(CC=2C=C3NC(=O)[C@@H]4CCCCN4C3=NC=2)CC1 ZBIXBAYEOLPYRG-QFIPXVFZSA-N 0.000 claims 1
- XPPZFNMKMXMGDQ-NRFANRHFSA-N 4-[4-[[(6as)-6-oxo-5,6a,7,8,9,10-hexahydrodipyrido[1,2-c:2',3'-f]pyrazin-3-yl]methyl]piperazin-1-yl]-3-chloro-n-methylbenzamide Chemical compound ClC1=CC(C(=O)NC)=CC=C1N1CCN(CC=2C=C3NC(=O)[C@@H]4CCCCN4C3=NC=2)CC1 XPPZFNMKMXMGDQ-NRFANRHFSA-N 0.000 claims 1
- NGGNIRQJTLCWRF-NRFANRHFSA-N 4-[4-[[(6as)-6-oxo-5,6a,7,8,9,10-hexahydrodipyrido[1,2-c:2',3'-f]pyrazin-3-yl]methyl]piperazin-1-yl]-3-fluoro-n-methylbenzamide Chemical compound FC1=CC(C(=O)NC)=CC=C1N1CCN(CC=2C=C3NC(=O)[C@@H]4CCCCN4C3=NC=2)CC1 NGGNIRQJTLCWRF-NRFANRHFSA-N 0.000 claims 1
- LABLKMYDBHRYDU-NRFANRHFSA-N 4-[4-[[(6as)-6-oxo-5,6a,7,8,9,10-hexahydrodipyrido[1,2-c:2',3'-f]pyrazin-3-yl]methyl]piperazin-1-yl]-3-methoxybenzonitrile Chemical compound COC1=CC(C#N)=CC=C1N1CCN(CC=2C=C3NC(=O)[C@@H]4CCCCN4C3=NC=2)CC1 LABLKMYDBHRYDU-NRFANRHFSA-N 0.000 claims 1
- UFGWTMXWFVFDRS-QFIPXVFZSA-N 4-[4-[[(6as)-6-oxo-5,6a,7,8,9,10-hexahydrodipyrido[1,2-c:2',3'-f]pyrazin-3-yl]methyl]piperazin-1-yl]-n,3-dimethylbenzamide Chemical compound CC1=CC(C(=O)NC)=CC=C1N1CCN(CC=2C=C3NC(=O)[C@@H]4CCCCN4C3=NC=2)CC1 UFGWTMXWFVFDRS-QFIPXVFZSA-N 0.000 claims 1
- MACJUVPHLCKOSP-QHCPKHFHSA-N 4-[4-[[(6as)-6-oxo-5,6a,7,8,9,10-hexahydrodipyrido[1,2-c:2',3'-f]pyrazin-3-yl]methyl]piperazin-1-yl]-n-cyclopropylbenzamide Chemical compound C=1C=C(N2CCN(CC=3C=C4NC(=O)[C@@H]5CCCCN5C4=NC=3)CC2)C=CC=1C(=O)NC1CC1 MACJUVPHLCKOSP-QHCPKHFHSA-N 0.000 claims 1
- DDFRWELTTVRQAR-QFIPXVFZSA-N 4-[4-[[(6as)-6-oxo-5,6a,7,8,9,10-hexahydrodipyrido[1,2-c:2',3'-f]pyrazin-3-yl]methyl]piperazin-1-yl]-n-ethylbenzamide Chemical compound C1=CC(C(=O)NCC)=CC=C1N1CCN(CC=2C=C3NC(=O)[C@@H]4CCCCN4C3=NC=2)CC1 DDFRWELTTVRQAR-QFIPXVFZSA-N 0.000 claims 1
- VCLLRFYIXDQALH-NRFANRHFSA-N 4-[4-[[(6as)-6-oxo-5,6a,7,8,9,10-hexahydrodipyrido[1,2-c:2',3'-f]pyrazin-3-yl]methyl]piperazin-1-yl]-n-methylbenzamide Chemical compound C1=CC(C(=O)NC)=CC=C1N1CCN(CC=2C=C3NC(=O)[C@@H]4CCCCN4C3=NC=2)CC1 VCLLRFYIXDQALH-NRFANRHFSA-N 0.000 claims 1
- FGCMPNDBDHIPKZ-FQEVSTJZSA-N 4-[4-[[(6as)-6-oxo-5,6a,7,8,9,10-hexahydrodipyrido[1,2-c:2',3'-f]pyrazin-3-yl]methyl]piperazin-1-yl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1N1CCN(CC=2C=C3NC(=O)[C@@H]4CCCCN4C3=NC=2)CC1 FGCMPNDBDHIPKZ-FQEVSTJZSA-N 0.000 claims 1
- SOFYSVVCSBNXKC-NRFANRHFSA-N 4-[4-[[(6as)-6-oxo-5,6a,7,8,9,10-hexahydrodipyrido[1,2-c:2',3'-f]pyrazin-3-yl]methyl]piperazin-1-yl]benzonitrile Chemical compound O=C([C@@H]1CCCCN1C1=NC=2)NC1=CC=2CN(CC1)CCN1C1=CC=C(C#N)C=C1 SOFYSVVCSBNXKC-NRFANRHFSA-N 0.000 claims 1
- LZNRFJNVVOWKJW-UHFFFAOYSA-N 6-[4-[(6-oxo-6a,7,9,10-tetrahydro-5h-pyrido[1,2]pyrazino[4,6-a][1,4]oxazin-3-yl)methyl]piperazin-1-yl]pyridine-3-carbonitrile Chemical compound C=1N=C2N3CCOCC3C(=O)NC2=CC=1CN(CC1)CCN1C1=CC=C(C#N)C=N1 LZNRFJNVVOWKJW-UHFFFAOYSA-N 0.000 claims 1
- GAWIEEZOQHXVNT-SFHVURJKSA-N 6-[4-[[(6ar)-6-oxo-6a,7,9,10-tetrahydro-5h-pyrido[1,2]pyrazino[4,6-a][1,4]thiazin-3-yl]methyl]piperazin-1-yl]pyridine-3-carbonitrile Chemical compound O=C([C@@H]1CSCCN1C1=NC=2)NC1=CC=2CN(CC1)CCN1C1=CC=C(C#N)C=N1 GAWIEEZOQHXVNT-SFHVURJKSA-N 0.000 claims 1
- FZWWANDEDKIQPP-NRFANRHFSA-N 6-[4-[[(6as)-6-oxo-5,6a,7,8,9,10-hexahydrodipyrido[1,2-c:2',3'-f]pyrazin-3-yl]methyl]piperazin-1-yl]-n-cyclopropylpyridine-3-carboxamide Chemical compound C=1C=C(N2CCN(CC=3C=C4NC(=O)[C@@H]5CCCCN5C4=NC=3)CC2)N=CC=1C(=O)NC1CC1 FZWWANDEDKIQPP-NRFANRHFSA-N 0.000 claims 1
- ZDGXRCQFKRVVIL-FQEVSTJZSA-N 6-[4-[[(6as)-6-oxo-5,6a,7,8,9,10-hexahydrodipyrido[1,2-c:2',3'-f]pyrazin-3-yl]methyl]piperazin-1-yl]-n-ethylpyridine-3-carboxamide Chemical compound N1=CC(C(=O)NCC)=CC=C1N1CCN(CC=2C=C3NC(=O)[C@@H]4CCCCN4C3=NC=2)CC1 ZDGXRCQFKRVVIL-FQEVSTJZSA-N 0.000 claims 1
- SOMUEPFLWQLAHI-IBGZPJMESA-N 6-[4-[[(6as)-6-oxo-5,6a,7,8,9,10-hexahydrodipyrido[1,2-c:2',3'-f]pyrazin-3-yl]methyl]piperazin-1-yl]-n-methylpyridine-3-carboxamide Chemical compound N1=CC(C(=O)NC)=CC=C1N1CCN(CC=2C=C3NC(=O)[C@@H]4CCCCN4C3=NC=2)CC1 SOMUEPFLWQLAHI-IBGZPJMESA-N 0.000 claims 1
- CPIWDUPVMRMJGX-NRFANRHFSA-N 6-[4-[[(6as)-6-oxo-5,6a,7,8,9,10-hexahydrodipyrido[1,2-c:2',3'-f]pyrazin-3-yl]methyl]piperazin-1-yl]-n-propan-2-ylpyridine-3-carboxamide Chemical compound N1=CC(C(=O)NC(C)C)=CC=C1N1CCN(CC=2C=C3NC(=O)[C@@H]4CCCCN4C3=NC=2)CC1 CPIWDUPVMRMJGX-NRFANRHFSA-N 0.000 claims 1
- RZRQRKRPOQCSTC-IBGZPJMESA-N 6-[4-[[(6as)-6-oxo-5,6a,7,8,9,10-hexahydrodipyrido[1,2-c:2',3'-f]pyrazin-3-yl]methyl]piperazin-1-yl]pyridine-3-carbonitrile Chemical compound O=C([C@@H]1CCCCN1C1=NC=2)NC1=CC=2CN(CC1)CCN1C1=CC=C(C#N)C=N1 RZRQRKRPOQCSTC-IBGZPJMESA-N 0.000 claims 1
- KTAXABSTLWNGRL-SFHVURJKSA-N 6-[4-[[(6as)-6-oxo-5,6a,7,8,9,10-hexahydrodipyrido[1,2-c:2',3'-f]pyrazin-3-yl]methyl]piperazin-1-yl]pyridine-3-carboxylic acid Chemical compound N1=CC(C(=O)O)=CC=C1N1CCN(CC=2C=C3NC(=O)[C@@H]4CCCCN4C3=NC=2)CC1 KTAXABSTLWNGRL-SFHVURJKSA-N 0.000 claims 1
- DBNSANBLGQKATD-UHFFFAOYSA-N 7-[4-(4-chloro-phenyl)-piperazin-1-ylmethyl]-1,3,4,10a-tetrahydro-2h,9h-2,4-a,5,9-tetraaza-phenanthren-10-one Chemical compound C1=CC(Cl)=CC=C1N1CCN(CC=2C=C3NC(=O)C4CNCCN4C3=NC=2)CC1 DBNSANBLGQKATD-UHFFFAOYSA-N 0.000 claims 1
- SVBGTYBZLYOQRB-UHFFFAOYSA-N 7-[4-(4-chloro-phenyl)-piperazin-1-ylmethyl]-10-oxo-1,3,4,9,10,10a-hexahydro-2,4-a,5,9-tetraaza-phenanthrene-2-carboxylic acid tert-butyl ester Chemical compound C1N(C(=O)OC(C)(C)C)CCN(C2=NC=3)C1C(=O)NC2=CC=3CN(CC1)CCN1C1=CC=C(Cl)C=C1 SVBGTYBZLYOQRB-UHFFFAOYSA-N 0.000 claims 1
- XGKVMPFQCVRLMP-UHFFFAOYSA-N 7-[4-(4-chloro-phenyl)-piperazin-1-ylmethyl]-2-methyl-1,3,4,10a-tetrahydro-2h,9h-2,4-a,5,9-tetraaza-phenanthren-10-one Chemical compound C1N(C)CCN(C2=NC=3)C1C(=O)NC2=CC=3CN(CC1)CCN1C1=CC=C(Cl)C=C1 XGKVMPFQCVRLMP-UHFFFAOYSA-N 0.000 claims 1
- VCHZDMQYSYOEFM-UHFFFAOYSA-N C(C1=CC=CC=C1)(=O)NN1CCN(CC1)CC1=CC=2NC(C3N(C2N=C1)CCCC3)=O Chemical compound C(C1=CC=CC=C1)(=O)NN1CCN(CC1)CC1=CC=2NC(C3N(C2N=C1)CCCC3)=O VCHZDMQYSYOEFM-UHFFFAOYSA-N 0.000 claims 1
- JBTCCOBHGHULAO-SFHVURJKSA-N C1=C(C#N)C(F)=C(F)C(N2CCN(CC=3C=C4NC(=O)[C@@H]5CCCN5C4=NC=3)CC2)=C1 Chemical compound C1=C(C#N)C(F)=C(F)C(N2CCN(CC=3C=C4NC(=O)[C@@H]5CCCN5C4=NC=3)CC2)=C1 JBTCCOBHGHULAO-SFHVURJKSA-N 0.000 claims 1
- RENADBZEQAMUML-IBGZPJMESA-N C1=C(Cl)C(F)=CC(N2CCN(CC=3C=C4NC(=O)[C@@H]5CCCN5C4=NC=3)CC2)=C1 Chemical compound C1=C(Cl)C(F)=CC(N2CCN(CC=3C=C4NC(=O)[C@@H]5CCCN5C4=NC=3)CC2)=C1 RENADBZEQAMUML-IBGZPJMESA-N 0.000 claims 1
- XKGSUZRJYBRPNL-UHFFFAOYSA-N C1=C2N(CC=N1)C(C=C2)=O Chemical compound C1=C2N(CC=N1)C(C=C2)=O XKGSUZRJYBRPNL-UHFFFAOYSA-N 0.000 claims 1
- JZOZHLOLABSZBS-FQEVSTJZSA-N C1=CC(Cl)=CC=C1C(CC1)=CCN1CC1=CN=C(N2[C@@H](CCC2)C(=O)N2)C2=C1 Chemical compound C1=CC(Cl)=CC=C1C(CC1)=CCN1CC1=CN=C(N2[C@@H](CCC2)C(=O)N2)C2=C1 JZOZHLOLABSZBS-FQEVSTJZSA-N 0.000 claims 1
- WBJHJWGWEXEORY-FQEVSTJZSA-N C1=CC(Cl)=CC=C1C1CCN(CC=2C=C3NC(=O)[C@@H]4CCCN4C3=NC=2)CC1 Chemical compound C1=CC(Cl)=CC=C1C1CCN(CC=2C=C3NC(=O)[C@@H]4CCCN4C3=NC=2)CC1 WBJHJWGWEXEORY-FQEVSTJZSA-N 0.000 claims 1
- WBJHJWGWEXEORY-HXUWFJFHSA-N C1=CC(Cl)=CC=C1C1CCN(CC=2C=C3NC(=O)[C@H]4CCCN4C3=NC=2)CC1 Chemical compound C1=CC(Cl)=CC=C1C1CCN(CC=2C=C3NC(=O)[C@H]4CCCN4C3=NC=2)CC1 WBJHJWGWEXEORY-HXUWFJFHSA-N 0.000 claims 1
- SDNBNPROTAHBEE-IBGZPJMESA-N C1=CC=C2NC(N3CCN(CC3)CC=3C=C4NC([C@@H]5CCCN5C4=NC=3)=O)=NC2=C1 Chemical compound C1=CC=C2NC(N3CCN(CC3)CC=3C=C4NC([C@@H]5CCCN5C4=NC=3)=O)=NC2=C1 SDNBNPROTAHBEE-IBGZPJMESA-N 0.000 claims 1
- WXBLLBRLSCXWGR-SFHVURJKSA-N C1=CC=C2OC(N3CCN(CC3)CC=3C=C4NC([C@@H]5CCCN5C4=NC=3)=O)=NC2=C1 Chemical compound C1=CC=C2OC(N3CCN(CC3)CC=3C=C4NC([C@@H]5CCCN5C4=NC=3)=O)=NC2=C1 WXBLLBRLSCXWGR-SFHVURJKSA-N 0.000 claims 1
- QBUCSPRGWDTWPG-PKHIMPSTSA-N C1CN(CC=2C=C3NC(=O)[C@@H]4CCCN4C3=NC=2)C(C)CN1C1=CC=CC=N1 Chemical compound C1CN(CC=2C=C3NC(=O)[C@@H]4CCCN4C3=NC=2)C(C)CN1C1=CC=CC=N1 QBUCSPRGWDTWPG-PKHIMPSTSA-N 0.000 claims 1
- DKWGEIRZJNQGTK-FQEVSTJZSA-N CC1=CC=CC(N2CCN(CC=3C=C4NC(=O)[C@@H]5CCCN5C4=NC=3)CC2)=C1 Chemical compound CC1=CC=CC(N2CCN(CC=3C=C4NC(=O)[C@@H]5CCCN5C4=NC=3)CC2)=C1 DKWGEIRZJNQGTK-FQEVSTJZSA-N 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- KBKQCFJUIRKMAR-IBGZPJMESA-N FC1=CC(C#N)=CC(F)=C1N1CCN(CC=2C=C3NC(=O)[C@@H]4CCCN4C3=NC=2)CC1 Chemical compound FC1=CC(C#N)=CC(F)=C1N1CCN(CC=2C=C3NC(=O)[C@@H]4CCCN4C3=NC=2)CC1 KBKQCFJUIRKMAR-IBGZPJMESA-N 0.000 claims 1
- OACWEWKMBVOYGR-UHFFFAOYSA-N N#CC1=NC=CC=C1N1CCN(CC2=CC(NC(C3N4CCC3)=O)=C4N=C2)CC1 Chemical compound N#CC1=NC=CC=C1N1CCN(CC2=CC(NC(C3N4CCC3)=O)=C4N=C2)CC1 OACWEWKMBVOYGR-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- QQALHMPYPPZKKK-FQEVSTJZSA-N O=C([C@@H]1CCCN1C1=NC=2)NC1=CC=2CN(CC1)CCN1C1=CC=C(C#N)C=C1 Chemical compound O=C([C@@H]1CCCN1C1=NC=2)NC1=CC=2CN(CC1)CCN1C1=CC=C(C#N)C=C1 QQALHMPYPPZKKK-FQEVSTJZSA-N 0.000 claims 1
- UXMVKWNIUJKWFR-SFHVURJKSA-N O=C([C@@H]1CCCN1C1=NC=2)NC1=CC=2CN(CC1)CCN1C1=CC=C(C#N)C=N1 Chemical compound O=C([C@@H]1CCCN1C1=NC=2)NC1=CC=2CN(CC1)CCN1C1=CC=C(C#N)C=N1 UXMVKWNIUJKWFR-SFHVURJKSA-N 0.000 claims 1
- ILTFFEOFCFQLET-IBGZPJMESA-N O=C([C@@H]1CCCN1C1=NC=2)NC1=CC=2CN(CC1)CCN1C1=CC=C(C#N)N=C1 Chemical compound O=C([C@@H]1CCCN1C1=NC=2)NC1=CC=2CN(CC1)CCN1C1=CC=C(C#N)N=C1 ILTFFEOFCFQLET-IBGZPJMESA-N 0.000 claims 1
- UOMSIABEOJIXCJ-KRWDZBQOSA-N O=C([C@@H]1CCCN1C1=NC=2)NC1=CC=2CN(CC1)CCN1C1=CC=CC=N1 Chemical compound O=C([C@@H]1CCCN1C1=NC=2)NC1=CC=2CN(CC1)CCN1C1=CC=CC=N1 UOMSIABEOJIXCJ-KRWDZBQOSA-N 0.000 claims 1
- YTICAWSKYOQZOS-INIZCTEOSA-N O=C([C@@H]1CCCN1C1=NC=2)NC1=CC=2CN(CC1)CCN1C1=NC=CC=N1 Chemical compound O=C([C@@H]1CCCN1C1=NC=2)NC1=CC=2CN(CC1)CCN1C1=NC=CC=N1 YTICAWSKYOQZOS-INIZCTEOSA-N 0.000 claims 1
- LREQSRNGKCAJLQ-HNNXBMFYSA-N O=C([C@@H]1CCCN1C1=NC=2)NC1=CC=2CN(CC1)CCN1C1=NC=NC=N1 Chemical compound O=C([C@@H]1CCCN1C1=NC=2)NC1=CC=2CN(CC1)CCN1C1=NC=NC=N1 LREQSRNGKCAJLQ-HNNXBMFYSA-N 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000005708 carbonyloxy group Chemical group [*:2]OC([*:1])=O 0.000 claims 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 1
- 125000004367 cycloalkylaryl group Chemical group 0.000 claims 1
- DWHFRZOTMVVCMV-NRFANRHFSA-N ethyl 4-[4-[[(6ar)-6-oxo-6a,7,9,10-tetrahydro-5h-pyrido[1,2]pyrazino[4,6-a][1,4]thiazin-3-yl]methyl]piperazin-1-yl]benzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1N1CCN(CC=2C=C3NC(=O)[C@@H]4CSCCN4C3=NC=2)CC1 DWHFRZOTMVVCMV-NRFANRHFSA-N 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- RUZLIIJDZBWWSA-INIZCTEOSA-N methyl 2-[[(1s)-1-(7-methyl-2-morpholin-4-yl-4-oxopyrido[1,2-a]pyrimidin-9-yl)ethyl]amino]benzoate Chemical group COC(=O)C1=CC=CC=C1N[C@@H](C)C1=CC(C)=CN2C(=O)C=C(N3CCOCC3)N=C12 RUZLIIJDZBWWSA-INIZCTEOSA-N 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 0 CN1CCN(*)CC1 Chemical compound CN1CCN(*)CC1 0.000 description 7
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14674009P | 2009-01-23 | 2009-01-23 | |
| US61/146,740 | 2009-01-23 | ||
| US22887909P | 2009-07-27 | 2009-07-27 | |
| US61/228,879 | 2009-07-27 | ||
| PCT/US2010/021669 WO2010085570A1 (en) | 2009-01-23 | 2010-01-21 | Poly (ADP-Ribose) Polymerase (PARP) Inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012515786A JP2012515786A (ja) | 2012-07-12 |
| JP2012515786A5 true JP2012515786A5 (enExample) | 2013-03-14 |
| JP5567599B2 JP5567599B2 (ja) | 2014-08-06 |
Family
ID=42271897
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011548104A Expired - Fee Related JP5567599B2 (ja) | 2009-01-23 | 2010-01-21 | ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤 |
Country Status (23)
| Country | Link |
|---|---|
| US (5) | US7928105B2 (enExample) |
| EP (1) | EP2389379A1 (enExample) |
| JP (1) | JP5567599B2 (enExample) |
| KR (1) | KR101779137B1 (enExample) |
| CN (1) | CN102341394B (enExample) |
| AU (1) | AU2010206744B2 (enExample) |
| BR (1) | BRPI1007358A2 (enExample) |
| CA (1) | CA2750106A1 (enExample) |
| CL (1) | CL2011001754A1 (enExample) |
| CO (1) | CO6410305A2 (enExample) |
| CR (1) | CR20110452A (enExample) |
| DO (1) | DOP2011000237A (enExample) |
| EA (1) | EA020301B1 (enExample) |
| EC (1) | ECSP11011284A (enExample) |
| IL (1) | IL213993A (enExample) |
| MA (1) | MA33053B1 (enExample) |
| MX (1) | MX2011007741A (enExample) |
| MY (1) | MY152386A (enExample) |
| NZ (1) | NZ594322A (enExample) |
| PE (1) | PE20120418A1 (enExample) |
| SG (1) | SG172958A1 (enExample) |
| TN (1) | TN2011000339A1 (enExample) |
| WO (1) | WO2010085570A1 (enExample) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102341394B (zh) | 2009-01-23 | 2015-04-15 | 武田药品工业株式会社 | 聚(adp-核糖)聚合酶(parp)抑制剂 |
| JP5715625B2 (ja) | 2009-07-30 | 2015-05-07 | 武田薬品工業株式会社 | ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤 |
| US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
| EP2902030B1 (en) | 2010-05-14 | 2016-09-14 | Dana-Farber Cancer Institute, Inc. | Thienotriazolodiazepine compounds for treating neoplasia |
| CN103180318B (zh) | 2010-05-14 | 2017-05-10 | 达那-法伯癌症研究所 | 雄性避孕组合物以及使用方法 |
| WO2011143660A2 (en) | 2010-05-14 | 2011-11-17 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating leukemia |
| FI3461825T3 (fi) * | 2011-09-30 | 2023-08-17 | C&C Res Lab | Uusia heterosyklisiä johdannaisia ja niiden käyttöjä |
| KR20220137154A (ko) | 2012-01-20 | 2022-10-11 | 데니스 엠. 브라운 | 다형교모세포종 및 수모세포종을 비롯한 신생종양 질환 및 암 줄기세포의 치료를 위한 디안히드로갈락티톨 및 유사체를 비롯한 치환된 헥시톨의 용도 |
| EP2935261A1 (de) * | 2012-12-20 | 2015-10-28 | Bayer Pharma Aktiengesellschaft | Bet-proteininhibitorische dihydrochinoxalinone |
| CN103923088B (zh) * | 2013-01-11 | 2016-09-07 | 上海汇伦生命科技有限公司 | 2,5-二氮杂双环[2.2.1]庚烷类化合物和制备方法、其药用组合物及其在医药上的应用 |
| WO2014159392A1 (en) | 2013-03-14 | 2014-10-02 | Dana-Farber Cancer Institute, Inc. | Bromodomain binding reagents and uses thereof |
| US11491154B2 (en) | 2013-04-08 | 2022-11-08 | Dennis M. Brown | Therapeutic benefit of suboptimally administered chemical compounds |
| EP3019493B1 (de) * | 2013-07-09 | 2017-06-14 | Bayer Pharma Aktiengesellschaft | Modifizierte bet-proteininhibitorische dihydrochinoxalinone und dihydropyridopyrazinone |
| CA2918910A1 (en) | 2013-07-25 | 2015-01-29 | Dana-Farber Cancer Institute, Inc. | Inhibitors of transcription factors and uses thereof |
| KR20160104612A (ko) | 2013-07-26 | 2016-09-05 | 업데이트 파마 인코포레이트 | 비산트렌의 치료 효과 개선용 조성물 |
| EP3066101B1 (en) | 2013-11-08 | 2020-07-29 | Dana-Farber Cancer Institute, Inc. | Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors |
| JP2017504650A (ja) * | 2014-01-31 | 2017-02-09 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | ジアゼパン誘導体およびその使用 |
| JP2017504651A (ja) | 2014-01-31 | 2017-02-09 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | ジアゼパン誘導体の使用 |
| KR20160115953A (ko) | 2014-01-31 | 2016-10-06 | 다나-파버 캔서 인스티튜트 인크. | 디아미노피리미딘 벤젠술폰 유도체 및 그의 용도 |
| CN106456653A (zh) | 2014-02-28 | 2017-02-22 | 腾沙治疗公司 | 高胰岛素血症相关病症的治疗 |
| AU2015240465B2 (en) | 2014-04-04 | 2020-02-27 | Del Mar Pharmaceuticals | Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer |
| KR102310128B1 (ko) * | 2014-07-14 | 2021-10-06 | 주식회사 포스코 | 트리아진-피페라진 골격을 갖는 알파-헬릭스 유사체 및 이의 제조방법 |
| CN106793775B (zh) | 2014-08-08 | 2020-06-02 | 达纳-法伯癌症研究所股份有限公司 | 二氢碟啶酮衍生物及其用途 |
| JP2017526741A (ja) | 2014-08-08 | 2017-09-14 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | ジアゼパン誘導体およびその使用 |
| SG11201703414VA (en) | 2014-10-27 | 2017-05-30 | Tensha Therapeutics Inc | Bromodomain inhibitors |
| WO2016201370A1 (en) | 2015-06-12 | 2016-12-15 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| PE20181287A1 (es) | 2015-09-11 | 2018-08-07 | Dana Farber Cancer Inst Inc | Ciano tienotriazolpirazinas y usos de las mismas |
| HK1256419A1 (zh) | 2015-09-11 | 2019-09-20 | 达纳-法伯癌症研究所股份有限公司 | 乙酰胺噻吩並三唑並二氮雜環庚三烯及其用途 |
| SG10201913450PA (en) | 2015-11-25 | 2020-03-30 | Dana Farber Cancer Inst Inc | Bivalent bromodomain inhibitors and uses thereof |
| US11096909B2 (en) | 2016-04-06 | 2021-08-24 | University Of Oulu | Compounds for use in the treatment of cancer |
| DE102017005091A1 (de) | 2016-05-30 | 2017-11-30 | Bayer Pharma Aktiengesellschaft | Substituierte 3,4-Dihydropyrido[2,3-b]pyrazin-2(1H)-one |
| DE102017005089A1 (de) | 2016-05-30 | 2017-11-30 | Bayer Pharma Aktiengesellschaft | Substitulerte 3,4-Dihydrochinoxalin-2(1H)-one |
| EP3267192B1 (en) * | 2016-07-07 | 2020-08-19 | Alpha M.O.S. | Gas chromatograph comprising metal oxide sensors |
| CN106883232B (zh) * | 2017-03-31 | 2019-01-22 | 苏州康润医药有限公司 | 一种氮杂非那烯-3-酮的衍生物及其制备方法与应用 |
| CN114144413B (zh) * | 2019-07-19 | 2024-08-16 | 阿斯利康(瑞典)有限公司 | Parp1抑制剂 |
| CN111097386B (zh) * | 2019-12-26 | 2022-01-11 | 江苏大学 | 一种二维层状水稳定染料吸附剂及制备方法 |
| US11795158B2 (en) | 2020-06-25 | 2023-10-24 | Astrazeneca Ab | Chemical compounds |
| WO2022225934A1 (en) * | 2021-04-19 | 2022-10-27 | Xinthera, Inc. | Parp1 inhibitors and uses thereof |
| CA3213029A1 (en) * | 2021-04-22 | 2022-10-27 | Yuli Xie | Parp inhibitor containing piperazine structure, preparation method therefor and pharmaceutical use thereof |
| WO2022223022A1 (zh) * | 2021-04-23 | 2022-10-27 | 四川海思科制药有限公司 | 一种并环杂环衍生物及其在医药上的应用 |
| CN116710433A (zh) * | 2021-04-23 | 2023-09-05 | 成都百裕制药股份有限公司 | 一种选择性parp1抑制剂及其应用 |
| TW202304911A (zh) * | 2021-04-23 | 2023-02-01 | 大陸商南京明德新藥研發有限公司 | 吡啶醯胺類化合物 |
| WO2023025307A1 (en) * | 2021-08-27 | 2023-03-02 | Impact Therapeutics (Shanghai) , Inc | Substituted tricyclic compounds as parp inhibitors and use thereof |
| WO2023046034A1 (zh) * | 2021-09-22 | 2023-03-30 | 明慧医药（杭州）有限公司 | 一种含氮杂环化合物、其制备方法、其中间体及其应用 |
| WO2023046149A1 (zh) * | 2021-09-26 | 2023-03-30 | 张文燕 | 喹喔啉类化合物及其医药用途 |
| WO2023046158A1 (zh) * | 2021-09-26 | 2023-03-30 | 张文燕 | 氮杂喹啉酮类化合物及其医药用途 |
| CN118043322A (zh) * | 2021-09-30 | 2024-05-14 | 西藏海思科制药有限公司 | 含氮杂环衍生物parp抑制剂及其用途 |
| US20240391937A1 (en) * | 2021-09-30 | 2024-11-28 | Xizang Haisco Pharmaceutical Co., Ltd. | Bicyclic derivative parp inhibitor and use thereof |
| WO2023051716A1 (zh) * | 2021-09-30 | 2023-04-06 | 海思科医药集团股份有限公司 | 杂芳基衍生物parp抑制剂及其用途 |
| PE20241129A1 (es) | 2021-10-01 | 2024-05-24 | Xinthera Inc | Inhibidores de parp1 de azetidina y pirrolidina y usos de estos |
| WO2023061406A1 (zh) * | 2021-10-12 | 2023-04-20 | 微境生物医药科技(上海)有限公司 | 含三并环结构的parp抑制剂、及其制备方法和医药用途 |
| MX2024006074A (es) * | 2021-11-19 | 2024-06-28 | Kangbaida Sichuan Biotechnology Co Ltd | Inhibidor de parp1 selectivo y aplicacion del mismo. |
| WO2023096915A1 (en) * | 2021-11-24 | 2023-06-01 | Slap Pharmaceuticals Llc | Multicyclic compounds |
| KR20240144125A (ko) * | 2021-12-17 | 2024-10-02 | 키테라 (쑤저우) 바이오-파마슈티컬스 컴퍼니 리미티드 | Parp 억제제, 이를 포함하는 약제학적 조성물, 및 이의 용도 |
| MX2024008771A (es) * | 2022-01-13 | 2024-09-23 | Acerand Therapeutics Hong Kong Ltd | Derivado que contiene anillo de piperazino, su sal farmacéuticamente aceptable, su método de preparación y su aplicación. |
| CN118804916B (zh) | 2022-01-21 | 2025-04-01 | 新特拉有限公司 | Parp1抑制剂及其用途 |
| AU2023229992A1 (en) * | 2022-03-11 | 2024-10-10 | Impact Therapeutics (Shanghai), Inc. | Substituted tricyclic compounds as parp inhibitors and the use thereof |
| WO2023207284A1 (en) * | 2022-04-28 | 2023-11-02 | Ningbo Newbay Technology Development Co., Ltd | Piperazine derivatives as parp1 inhibitiors |
| IL316278A (en) | 2022-04-28 | 2024-12-01 | Xinthera Inc | TRICYCLIC PARP1 INHIBITORS AND THEIR USES |
| CN117263943A (zh) * | 2022-09-09 | 2023-12-22 | 轩竹生物科技股份有限公司 | 聚（adp核糖）聚合酶选择性抑制剂 |
| CN120112531A (zh) * | 2022-10-20 | 2025-06-06 | 成都赜灵生物医药科技有限公司 | 并杂环类化合物及其用途 |
| CN119948029A (zh) * | 2022-11-10 | 2025-05-06 | 上海海和药物研究开发股份有限公司 | 一种稠合三环类parp1抑制剂、其制备方法及用途 |
| IL320545A (en) * | 2022-11-10 | 2025-06-01 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Fused bicyclic compound |
| WO2024173781A1 (en) * | 2023-02-16 | 2024-08-22 | Ohio State Innovation Foundation | Type ii topoisomerase inhibitors and methods of making and using thereof |
| KR20250154499A (ko) * | 2023-03-01 | 2025-10-28 | 임팩트 테라퓨틱스 (상하이), 인코포레이티드 | Parp 억제제로서의 치환된 질소-함유 트리시클릭 화합물 및 이의 용도 |
| WO2024255697A1 (zh) * | 2023-06-13 | 2024-12-19 | 中国医药研究开发中心有限公司 | 含氮杂环类化合物及其医药用途 |
| US12258345B1 (en) | 2023-12-12 | 2025-03-25 | King Faisal University | Pyrrolo[3,2-c]isoquinoline-2,3-dione compounds as CK2 inhibitors |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4138564A (en) * | 1977-08-03 | 1979-02-06 | American Home Products Corporation | Tetrahydro[1H]pyrazino[1,2-a]azaquinoxalin-5(6H)-ones and derivatives thereof |
| US4446323A (en) * | 1983-05-23 | 1984-05-01 | American Home Products Corporation | Tetra- and hexa-hydropyrrolo(1,2-a)quinoxaline and azaquinoxaline derivatives |
| US5166344A (en) * | 1989-05-31 | 1992-11-24 | Berlex Laboratories, Inc. | Process for the preparation of imidazoquinoxalinones |
| US5055465A (en) * | 1989-05-31 | 1991-10-08 | Berlex Laboratories, Inc. | Imidazoquinoxalinones, their aza analogs and process for their preparation |
| DE4228095A1 (de) * | 1992-08-24 | 1994-03-03 | Asta Medica Ag | Neue 4,5-Dihydro-4-oxo-pyrrolo[1,2-a]chinoxaline und entsprechende Aza-analoga und Verfahren zu deren Herstellung |
| US5306819A (en) | 1992-08-27 | 1994-04-26 | Neurogen Corporation | Certain aryl a cycloalkyl fused imidazopyrazinols; and new class of GABA brain receptor ligands |
| TW274550B (enExample) * | 1992-09-26 | 1996-04-21 | Hoechst Ag | |
| US6197785B1 (en) * | 1997-09-03 | 2001-03-06 | Guilford Pharmaceuticals Inc. | Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity |
| US6121278A (en) * | 1997-09-03 | 2000-09-19 | Guilford Pharmaceuticals, Inc. | Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity |
| US6635642B1 (en) * | 1997-09-03 | 2003-10-21 | Guilford Pharmaceuticals Inc. | PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same |
| EP1339402B1 (en) * | 2000-12-01 | 2010-08-25 | Eisai Inc. | Azaphenanthridone derivatives and their use as parp inhibitors |
| GB0206219D0 (en) * | 2002-03-15 | 2002-05-01 | Ferring Bv | Non-Peptide GnRH antagonists |
| US7160888B2 (en) * | 2003-08-22 | 2007-01-09 | Warner Lambert Company Llc | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia |
| JP4948178B2 (ja) * | 2003-12-10 | 2012-06-06 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ポリ（ａｄｐ−リボース）ポリメラーゼ阻害剤としての置換６−シクロヘキシルアルキル置換２−キノリノンおよび２−キノキサリノン |
| BRPI0512261A (pt) * | 2004-06-17 | 2008-02-26 | Wyeth Corp | antagonistas de receptor de hormÈnio liberador de gonadotropina |
| AU2005327921A1 (en) | 2004-11-01 | 2006-08-31 | University Of Southern California | Novel compounds for treatment of cancer and disorders associated with angiogenesis function |
| US7947682B2 (en) * | 2004-12-29 | 2011-05-24 | University Of Southern California | Substituted N′-pyrrolo[1,2-a]quinoxalin-4-yl-hydrazides as anti-cancer agents |
| US20090093489A1 (en) * | 2004-12-29 | 2009-04-09 | University Of Southern California | Novel compounds for treatment of cancer and disorders associated with angiogenesis function |
| AU2006203946B2 (en) * | 2005-01-03 | 2009-07-23 | The Regents Of The University Of Michigan | Compositions and methods relating to novel compounds and targets thereof |
| WO2006125179A1 (en) | 2005-05-19 | 2006-11-23 | Xenon Pharmaceuticals Inc. | Tricyclic compounds and their uses as therapeutic agents |
| US7601716B2 (en) * | 2006-05-01 | 2009-10-13 | Cephalon, Inc. | Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors |
| GB0615809D0 (en) | 2006-08-09 | 2006-09-20 | Istituto Di Ricerche D Biolog | Therapeutic compounds |
| US20100113484A1 (en) * | 2006-12-13 | 2010-05-06 | Aska Pharmaceutical Co., Ltd. | Treating agent of uropathy |
| KR101563103B1 (ko) * | 2006-12-13 | 2015-10-23 | 아스카 세이야쿠 가부시키가이샤 | 퀴녹살린 유도체 |
| PH12012501544A1 (en) * | 2006-12-28 | 2024-06-03 | Abbvie Inc | Inhibitors of poly (adp-ribose) polymerase |
| US8466150B2 (en) * | 2006-12-28 | 2013-06-18 | Abbott Laboratories | Inhibitors of poly(ADP-ribose)polymerase |
| CN101302214B (zh) * | 2007-05-11 | 2012-06-20 | 江苏国华投资有限公司 | 芳烷基哌啶(嗪)衍生物及在治疗精神神经疾病中的应用 |
| AU2008345225A1 (en) * | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| CN102341394B (zh) | 2009-01-23 | 2015-04-15 | 武田药品工业株式会社 | 聚(adp-核糖)聚合酶(parp)抑制剂 |
| US8551996B2 (en) | 2009-02-20 | 2013-10-08 | Emory University | Compounds, compositions, methods of synthesis, and methods of treatment |
-
2010
- 2010-01-21 CN CN201080009854.6A patent/CN102341394B/zh not_active Expired - Fee Related
- 2010-01-21 JP JP2011548104A patent/JP5567599B2/ja not_active Expired - Fee Related
- 2010-01-21 WO PCT/US2010/021669 patent/WO2010085570A1/en not_active Ceased
- 2010-01-21 EA EA201170963A patent/EA020301B1/ru not_active IP Right Cessation
- 2010-01-21 PE PE2011001360A patent/PE20120418A1/es active IP Right Grant
- 2010-01-21 MX MX2011007741A patent/MX2011007741A/es active IP Right Grant
- 2010-01-21 KR KR1020117019556A patent/KR101779137B1/ko not_active Expired - Fee Related
- 2010-01-21 NZ NZ594322A patent/NZ594322A/xx not_active IP Right Cessation
- 2010-01-21 CA CA2750106A patent/CA2750106A1/en not_active Abandoned
- 2010-01-21 US US12/691,668 patent/US7928105B2/en not_active Expired - Fee Related
- 2010-01-21 MA MA34106A patent/MA33053B1/fr unknown
- 2010-01-21 EP EP10703547A patent/EP2389379A1/en not_active Withdrawn
- 2010-01-21 MY MYPI2011003399 patent/MY152386A/en unknown
- 2010-01-21 BR BRPI1007358-2A patent/BRPI1007358A2/pt not_active Application Discontinuation
- 2010-01-21 AU AU2010206744A patent/AU2010206744B2/en not_active Ceased
- 2010-01-21 SG SG2011050630A patent/SG172958A1/en unknown
-
2011
- 2011-03-04 US US13/041,200 patent/US8124606B2/en not_active Expired - Fee Related
- 2011-07-07 IL IL213993A patent/IL213993A/en not_active IP Right Cessation
- 2011-07-08 TN TN2011000339A patent/TN2011000339A1/fr unknown
- 2011-07-19 CL CL2011001754A patent/CL2011001754A1/es unknown
- 2011-07-22 DO DO2011000237A patent/DOP2011000237A/es unknown
- 2011-08-11 CO CO11102248A patent/CO6410305A2/es active IP Right Grant
- 2011-08-23 CR CR20110452A patent/CR20110452A/es unknown
- 2011-08-23 EC EC2011011284A patent/ECSP11011284A/es unknown
-
2012
- 2012-01-18 US US13/352,902 patent/US8450323B2/en not_active Expired - Fee Related
-
2013
- 2013-05-08 US US13/889,585 patent/US8822470B2/en not_active Expired - Fee Related
-
2014
- 2014-08-01 US US14/450,101 patent/US9187497B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012515786A5 (enExample) | ||
| JP5911638B2 (ja) | ベンゾチアゾール−６−イル酢酸誘導体およびｈｉｖ感染を処置するためのそれらの使用 | |
| JP2012532931A5 (enExample) | ||
| CN114502564A (zh) | Egfr抑制剂、组合物及其制备方法 | |
| RU2016140338A (ru) | Азаспиро производные в качестве антагонистов trpm8 | |
| JP2017531039A5 (enExample) | ||
| RU2018123779A (ru) | Новые соединения | |
| HRP20150185T1 (hr) | Inhibitori kinaza koji reguliraju signalne puteve u apoptozi | |
| JP2016500671A5 (enExample) | ||
| WO2013173506A2 (en) | Method of treating muscular degradation | |
| JP2016537384A5 (enExample) | ||
| JP2015517566A5 (enExample) | ||
| CA2682665A1 (en) | Triazinone and diazinone derivatives useful as hsp90 inhibitors | |
| JP2019536768A5 (enExample) | ||
| AU2005215257A1 (en) | Therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists | |
| EP2594270A2 (en) | The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc) | |
| JP2013505930A5 (enExample) | ||
| JP2020503291A5 (enExample) | ||
| JP2020503294A5 (enExample) | ||
| RU2007126551A (ru) | Соединения и композиции, как модуляторы стероидных рецепторов и активности кальциевых каналов | |
| JP2025529311A (ja) | 金属チャネル活性化剤を含む併用療法 | |
| JPWO2020052631A5 (enExample) | ||
| KR102727682B1 (ko) | 신규한 헤테로사이클릭 화합물 | |
| RU2025122871A (ru) | Новые гетероциклические соединения | |
| RU2021107655A (ru) | Соединения триазоло-пиримидина и их применение |